{"id":331001,"date":"2019-02-18T04:07:02","date_gmt":"2019-02-18T04:07:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=331001"},"modified":"2019-02-18T04:07:02","modified_gmt":"2019-02-18T04:07:02","slug":"23valent-pneumococcal-polysaccharide-vaccine-market-2019-global-share-trend-segmentation-analysis-industry-opportunities-and-forecast-to-2024","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/23valent-pneumococcal-polysaccharide-vaccine-market-2019-global-share-trend-segmentation-analysis-industry-opportunities-and-forecast-to-2024_331001.html","title":{"rendered":"23-Valent Pneumococcal Polysaccharide Vaccine Market 2019 Global Share, Trend, Segmentation, Analysis Industry, Opportunities and Forecast to 2024"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“\\”23-Valent Pneumococcal Polysaccharide Vaccine Market\\””<\/div>\n<\/div>\n<\/div>\n
Wiseguyreports.Com Added New Market Research Report On -\u201c23-Valent Pneumococcal Polysaccharide Vaccine Market 2019 Top Key Players, Segmentation, Industry Analysis and Demand Forecast to 2024 \u201d.<\/div>\n

 <\/p>\n

 <\/p>\n

Global<\/strong> 23-Valent Pneumococcal Polysaccharide Vaccine <\/strong>Market<\/strong><\/p>\n

WiseGuyRerports.com Presents “Global Capsule Endoscopy Market 2019 by Company, Regions, Type and Application, Forecast to 2024” New Document to its Studies Database. The Report Contain 108 Pages With Detailed Analysis. <\/strong><\/p>\n

Description <\/strong><\/p>\n

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.<\/p>\n

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.<\/p>\n

Scope of the Report:
<\/strong>North America is the largest supplier and consumption market of 23-Valent Pneumococcal Polysaccharide Vaccine, with a production market share nearly 70% and sales market share nearly 28% in 2015. Because Sanofipasteur, a competitor from Europe, transferred its vaccine type gradually, the production market share of North America in the world has enjoyed a dramatic increase.<\/p>\n

The second place is EU, following North America with production market share of 15% and sales market share nearly 20% in 2015.China is another important market of 23-Valent Pneumococcal Polysaccharide Vaccine, enjoying 10% production market share and 15% sales market share in 2015.<\/p>\n

The worldwide market for 23-Valent Pneumococcal Polysaccharide Vaccine is expected to grow at a CAGR of roughly 16.3%<\/strong> over the next five years, will reach 3830 million US$ in 2024, from 1550 million US$ in 2019, according to a new GIR (Global Info Research) study.<\/p>\n

 <\/strong><\/p>\n

Get sample Report @ <\/strong>https:\/\/www.wiseguyreports.com\/sample-request\/3741539-global-23-valent-pneumococcal-polysaccharide-vaccine-market-2019<\/strong><\/a><\/p>\n

This report focuses on the 23-Valent Pneumococcal Polysaccharide Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.<\/p>\n

Market Segment by Manufacturers, this report covers
<\/strong>MSD
Sanofipasteur
CDIBP<\/p>\n

Market Segment by Regions, regional analysis covers
<\/strong>North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)<\/p>\n

Market Segment by Type, covers
<\/strong>Single Dose Vial
Pre-filled Syringe<\/p>\n

Market Segment by Applications, can be divided into
<\/strong>For Children (2-10)
For Person (10-64)
For The Old (≥65)<\/p>\n

 <\/strong><\/p>\n

Complete Report Details <\/strong>@ <\/strong>https:\/\/www.wiseguyreports.com\/reports\/3741539-global-23-valent-pneumococcal-polysaccharide-vaccine-market-2019<\/strong><\/a><\/p>\n

 <\/strong><\/p>\n

Table of Contents -Major Key Points <\/strong><\/p>\n

1 Market Overview
<\/strong>1.1 23-Valent Pneumococcal Polysaccharide Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Single Dose Vial
1.2.2 Pre-filled Syringe
1.3 Market Analysis by Applications
1.3.1 For Children (2-10)
1.3.2 For Person (10-64)
1.3.3 For The Old (≥65)
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force<\/p>\n

2 Manufacturers Profiles
<\/strong>2.1 MSD
2.1.1 Business Overview
2.1.2 23-Valent Pneumococcal Polysaccharide Vaccine Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Sanofipasteur
2.2.1 Business Overview
2.2.2 23-Valent Pneumococcal Polysaccharide Vaccine Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 CDIBP
2.3.1 Business Overview
2.3.2 23-Valent Pneumococcal Polysaccharide Vaccine Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)<\/p>\n

……..CONTINUED<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“\\”23-Valent Pneumococcal Polysaccharide Vaccine Market\\”” Wiseguyreports.Com Added New Market Research Report On -\u201c23-Valent Pneumococcal Polysaccharide Vaccine Market 2019 Top Key Players, Segmentation, Industry Analysis and Demand Forecast to 2024 \u201d.     Global 23-Valent Pneumococcal Polysaccharide Vaccine Market WiseGuyRerports.com Presents … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-331001","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/331001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=331001"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/331001\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=331001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=331001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=331001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}